Skip to content

Advertisement

DARU Journal of Pharmaceutical Sciences

What do you think about BMC? Take part in

Open Access

Effect of memantine on post-operative cognitive dysfunction after cardiac surgeries: a randomized clinical trial

  • Saba Ghaffary1,
  • Padideh Ghaeli2,
  • Azita Hajhossein Talasaz2, 3Email author,
  • Abbasali Karimi3,
  • Maryam Noroozian4,
  • Abbas Salehiomran3 and
  • Arash Jalali3
DARU Journal of Pharmaceutical Sciences201725:24

https://doi.org/10.1186/s40199-017-0190-0

Received: 18 April 2017

Accepted: 6 November 2017

Published: 21 November 2017

Abstract

Background

Post-operative cognitive dysfunction (POCD) is an important complication of cardiac surgeries. Glutamate plays a critical role in physiologic and pathologic conditions in the brain. Due to the role of glutamate in ischemia, this study is designed to identify the effect of memantine in prevention of POCD early and late after cardiac surgeries.

Methods

In this randomized clinical trial, 172 patients with ages 45–75 years old who underwent elective cardiac surgery were enrolled. For patients in memantine group, 5 mg of memantine per day administered at least 48 h before surgery and increased to 10 mg per day during the first 24 h after surgery and continued for 3 months. A brief Wechsler memory test (WMT) was administered before, three to 5 days after, and 3 months after surgery for both groups.

Results

Both groups demonstrate standard pattern of cognitive dysfunction after surgery and in follow up. Pre- and post-operative WMT score showed significant improvement in memantine compared to control group (P < 0.001) both in unadjusted and adjusted with confounding factor analysis. Unadjusted pre-, post-operative, and follow up WMT score improved significantly after 3 months in memantine group (P = 0.006).

Conclusion

Pre-operative administration of memantine protects patients from POCD following cardiac surgeries. In addition, it improves cognitive function 3 months after surgery.

Trial registration

The trial was registered in the Iranian Registry of Clinical Trials (registration number: IRCT201303168698N12).

Graphical abstract

Memantin effect on POCD.

Keywords

Post-operative cognition dysfunction (POCD)GlutamateWechsler memory test (WMT)MemantineCardiac surgeries

Background

Post-operative cognition dysfunction (POCD), including deficits of memory, concentration and psychomotor speed is one of the neurologic complications after cardiac surgeries [1]. Different theories have been suggested for intraoperative mechanisms and pathophysiology of POCD. The formation of cerebral microemboli, Inflammation, anesthesia, hyperglycemia, oxygenation, speed of cardiopulmonary bypass rewarming temperature, hypoxia after surgery, duration of surgery, alterations in the cerebral perfusion and temperature change are some mechanisms suggested for POCD [2]. The cognitive dysfunction incidence is highest at discharge (50 to 80%) and is reduced to 10 to 30% in 6 months [3]. Although cognitive performance improves a year after cardiac surgery, it starts to decline from 1 to 5 years and reaches to 42% [4]. The exact pathophysiology of neurological complications after cardiac surgeries has not been clearly determined [5].

Glutamate plays a major role in many neurologic functions. Its level rise 50 fold the normal value within a short time in acute injury and lead to cell death following injury [6]. In addition, cells are vulnerable to physiologic concentrations of glutamate in pathologic conditions [7]. It should be mentioned that the normal function of N-methyl-D-aspartate (NMDA) receptor is critical in learning and memory formation. Subsequently, it is very important to preserve normal physiologic activity of NMDA receptors in order to preserve the normal neurological functions and avoid clinical side effects [8].

Memantine is the first uncompetitive, low-to-moderate affinity antagonist of NMDA receptor. Because of its affinity for the receptor, it is not leading to learning impairment or psycho-mimetic dysfunction like ketamine. Based on the critical role of glutamate in acute brain injury, and proven effect of memantine on memory we hypothesized that memantine may have a protective effect on POCD.

Methods

Patient enrollment

After institutional review board approval 172 patients (82 in memantine and 90 in control groups), who were undergoing elective cardiac surgery, assigned to this open-label randomized clinical trial. Participants younger than 45 and older than 75, and patients with a history of symptomatic cerebrovascular disease, stroke, seizure, psychiatric illness, active liver disease, or inability to calculate (due to perform Wechsler test) were excluded from enrollment. All surgeries were performed on-pump and operated by the same medical team under the same conditions. Simple randomization was conducted in this study by using computer-generated random sequence.

Measurement of Neurocognitive function

A brief neurocognitive test battery (Wechsler Memory Test) was administered before surgery and three to 5 days after surgery for both memantine and control groups. Wechsler Memory Test (WMT) is a memory assessment test which composed of seven different parts to assess the different parts of memory [9]. Assessments were performed individually by the same researcher (Trained resident of Pharmacotherapy). The assessment was performed without any interruption and in a quiet place for all patients before and after surgery.

WMT evaluates the followings: 1) Asking six questions to distinguish a patient who has aphasia or senile dementia; 2) Asking five questions regarding orientation to time and place; 3) Ability of mind control by special digits pattern; 4) Ability of subjects to recall the details of read text; 5) Ability to count separate digits in forward and reverse orders; 6) Dozens of words with or without any association in meaning was read to patients to assess ability to remember the association between words; 7) Assess the ability of subjects to reproduce a series of geometric shapes after a 10-s exposure [9].

The sum of scores from different parts of Wechsler memory test is added with the age constant. Then the new score is adjusted with respect to the standard Wechsler memory test table to reach the final score.

Intervention

For patients who randomly allocated to memantine group, 5 mg of memantine per day administered at least 48 h before surgery and increased to 10 mg per day (5 mg bid) during first 24 h after surgeries. Memantine 10 mg/day continued for patients until 3 months after discharge. Memantine was tolerated well and no patient reports any cardiac or non-cardiac side effects during administration. Memantine does not have any interaction with all administered medications and procedures during hospitalization for cardiac surgeries and did not change any cardiac parameters.

Standard protocol approval, registration and patient consents

The protocol of the present study was approved by the local Ethics Committee of Tehran Heart Center, Tehran University of Medical Sciences, Iran on 12 March 2013. The trial was registered in the Iranian Registry of Clinical Trials (registry number: IRCT201303168698N12). All patients were informed about the trial and gave a written informed consent before the study initiation.

Follow up

We had 3 months period of follow up for all patients in both memantine and control groups. After 3 months from discharge, patients were referred to the risk factor follow up clinic. Patients cognitive functions were evaluated by the same Wechsler memory test in both groups. All tests were performed in a quiet room without any interruption. Patients who were administered 10 mg memantine were asked about the adherence to the medication. Patients who did not continue memantine after discharge and could not complete the 3 months of medication period excluded from follow up.

Statistical analysis

Continuous variables were described with mean and standard deviation (SD) or median with 25th and 75th quartiles whenever the variables did not normally distributed. They were compared between intervention groups using independent samples t-test or Mann-Whitney U-test. Categorical variables were expressed with frequency and percentage, and were compared between memantine and control groups applying chi-squared or Fisher’s exact test. Post-operative WMT score and WMT score change were compared between intervention groups adjusting for confounder variables using multiple linear regression models. WMT score change for patients who were followed up 3 months after surgery were analyzed applying repeated measures analysis of variance (ANOVA). p values less than or equal to 0.05 were considered statistically significant. Statistical analysis was performed using IBM SPSS statistics for Windows, version 20.0.

Results

In this study, 500 patients were screened for eligibility from which 255 did not meet the inclusion criteria, 40 refused to be included in the trial and 15 excluded because of other reasons. Finally, 190 patients were randomized in two groups. There were 18 dropouts during the study, that is, 13 in memantine group and five in the control group. Therefore, 172 patients, 82 in the memantine and 90 in the control group, completed the period of hospitalization part of the study. From 172 patients, 22 and 31 individuals did not show up for follow up in memantine and control groups, respectively (Fig. 1).
Fig. 1

Screening, randomization and follow up of study participants

From 172 patients 145 were isolated coronary artery bypass graft (CABG) (84.3%), 14 were CABG plus valve replacement (8.1%), six patients were CABG plus other type of surgery (3.5%), and seven were valve or other type of surgery (4.1%).

The corresponding pre- and post-operative data were included in the final analysis. Our analysis shows that WMT score improves after 3 months in both groups (memantine and control) with different trend of improvement during this 3 months (p = 0.02; Fig. 2). From baseline parameters, being smoker, dyslipidemia, pre-operative antiplatelet consumption, blood transfusion, LDH level, cross clamp time and perfusion time were significantly different between groups and known as confounding factors (p < 0.05; Tables 1 and 2).
Fig. 2

Pre- and post-operative WMT score in all patients

Table 1

Demographic and clinical characteristics of patients (Categorical data)

Parameters

Control

n = 90(%)

Memantine

n = 82(%)

p value

Sex

Female

10(11.1)

9(10.9)

0.586

Male

80(88.9)

73(89.0)

0.586

Risk Factors*

Current Smoker

12/89(13.5)

26(31.7)

0.004

Alcohol Consumption

15 (16.7)

19(23.2)

0.190

Diabetes

30(33.3)

30(36.6)

0.387

Dyslipidemia

46(51.1)

56(68.3)

0.016

Hypertension

45(50.0)

44(53.7)

0.372

Positive Family History

40(44.4)

30(36.6)

0.186

Myocardial Infarct

23(25.6)

33(40.2)

0.260

CHF

4(4.4)

7(8.5)

0.217

Pre-operative Medication*

β-Blocker

73/87(83.9)

72/78(92.3)

0.780

CCB

13/87(14.9)

9/78(11.5)

0.341

Nitrates

75/87(86.2)

69/78(88.5)

0.422

Diuretics

21/87(24.1)

20/78(25.6)

0.482

ACEI

31/87(35.6)

29/78(37.2)

0.482

ARB

31/87(35.6)

25/78(32.1)

0.375

Anticoagulation

21/87(24.1)

25/78(32.1)

0.169

Digoxin

5/87(5.7)

5/78(6.4)

0.556

Amiodarone

2/87(2.3)

1/78(1.3)

0.541

Oral antihyperglycemic Agent

14/88(15.9)

16/78(20.5)

0.285

Insulin

14/88(15.9)

13/78(16.7)

0.530

Bronchodilator

11/88(12.5)

6/78(7.7)

0.224

PPI

7/17(41.2)

17/57(29.8)

0.276

Antiplatelet

69/87(79.3)

51/78(65.4)

0.034

Complication*

Blood Transfusion

47/87(54.0)

27/75(36.0)

0.016

* p values are generated by Chi-squared test

p values are generated by Fisher’s exact test

Categorical variables are presented in percent change (%). CHF chronic heart failure, CCB calcium channel blocker, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, PPI proton pump inhibitor

Table 2

Demographic and clinical characteristics of patients (Continuous data)

Parametersa,b

Control

Memantine

p value

Age

56.59 ± 6.71

56.39 ± 7.15

0.277

BMI (kg/m2)

26.76 ± 3.37

26.98 ± 4.29

0.250

HDL (mg/dL)

35.82 ± 8.15

36.25 ± 11.25

0.174

LDL (mg/dL)

90.30 ± 32.50

93.14 ± 33.52

0.755

LDH (IU/L)

245.53 ± 88.32

185.18 ± 59.76

<0.001

EF

46.69 ± 8.35

44.46 ± 9.50

0.339

Total Graft

3.42 ± 0.98

3.52 ± 1.03

0.841

Pre-operative WMT score

111.44 ± 15.30

113.90 ± 14.03

0.323

FBS (mg/dL)

96 (85–117)

96.5 (89–117)

0.557

Cholesterol (mg/dL)

146 (113.7–169.5)

146 (118–189)

0.447

Triglycerides (mg/dL)

134.5 (92.7–166.2)

124 (101–186)

0.530

Serum Creatinine (mg/dL)

0.9 (0.8–1)

0.8 (0.8–1)

0.425

Cross Clamp Time (Minute)

41 (30–50)

45 (40–59)

0.002

Perfusion Time (Minute)

70 (55–90)

80 (66.2–100.8)

0.005

Continuous variables are described in mean ± standard deviation (SD) and median ± range

aParametric variables are analyzed with Student t test

bNon-parametric variables are analyzed with Mann whitney u test. BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein, LDH lactate dehydrogenase, EF ejection fraction, WMT Wechsler memory test, FBS fasting blood sugar

The baseline levels of cognition were in the same range and did not differ statistically between groups (p = 0.275). The mean value of pre-operative WMT score in control group decreases from 111.44 (±15.31) to 104.64 (±14.77) whereas it increases from 113.90 (±14.03) to 116.42 (±15.36) in memantine group (p < 0.001). In addition, the change of WMT score mean pre- and post-operatively showed improvement in memantine group (2.5 score), while this change is negative in control group (−6.8 score with p < 0.001). Furthermore, after adjustment with confounding factors WMT score was significantly higher in memantine group (p < 0.001). Unadjusted effect of memantine administration 3 months after surgery significantly improved the WMT score (p = 0.006). Whereas, adjusted data with confounding factors did not show any significant effect after 3 months. The trend of pre- and post-operative and follow up WMT scores in patients who do not miss in follow up are illustrated in Fig. 3. In addition, the scores for the various memory domains are presented in Table 3.
Fig. 3

Trend of pre- and post-operative and after 3 months WMT scores in patients who followed up

Table 3

WMT Scores for the various memory domains

Group

Personal and current information

Orientation

Mind control

Logical memory

Memory span

Associate learning

Illustration reproduction

Total

Corrected score with age

Baseline Test

5.62650

4.975904

8.795181

6.180723

11.31325

12.27711

10.44578

59.49398

113.5663

Control

5.80198

4.980198

8.158416

5.435644

9.98019

12.16832

9.62376

56.17822

108.1980

After Test

5.65060

4.987952

8.795181

6.843373

10.51807

13.44578

10.73494

60.95181

116.1446

Control

5.77227

4.970297

7.891089

5.366337

8.36633

11.13861

9.24752

52.65347

101.8119

Follow up Test

5.71428

5.053571

8.964286

4.964286

9.94642

15.41071

11.98214

61.85455

118.5536

Control

5.81818

4.984848

7.984848

4.075758

9.66667

14

10.51515

57.75758

109.6970

Discussion

Prevention of POCD is very important due to its extensive effect on different aspects of patient life after surgery. Memantine is not only an antagonist of NMDA but also plays a neuroprotective role against neuronal degeneration of amyloid beta (Aβ) [10]. Memantine is a safe medication and does not have any caution in patients with cardiovascular disease. Subsequently, it was chosen as a novel medication before cardiac surgery to protect patients from POCD. In this study, both control and memantine groups had the same range of cognitive function at baseline before surgery. However, our results show that administration of 5 mg/day of memantine at least 48 h before surgery, and an increased dose in 24 h after surgery to 10 mg/day, decreases the POCD significantly in comparison to the control group. In addition, it is demonstrated that patients who received 10 mg/day of memantine after surgery for 3 months, experience a better cognitive function in with higher score of WMT after 3 months (unadjusted). It seems that the high number of patients lost to follow up is the reason for insignificant results in adjusted analysis with confounding factors.

In previous studies, other N-methyl-D-aspartate (NMDA) antagonists role on cognitive dysfunction after surgery and traumatic brain injury (TBI) have been studied by several researchers. In a double-blind, placebo-controlled, crossover trial by Meythaler et al., amantadine was administered within the first 24 h to the patients who had a TBI with a Glasgow Coma Scale score of 10 or less. In their study patients divided into two groups. Group 1 received amantadine the first 6 weeks after injury and then placebo for the second 6 weeks, whereas group 2 received placebo and amantadine in the first and second 6 weeks, respectively. Their results show that cognitive function improves more rapidly in patients in group 1 who had started on amantadine in the first 3 months after TBI [11].

The effect of ketamine during anesthetic induction was compared with normal saline in cardiac surgeries [12]. The data showed that patients who received ketamine in anesthesia induction had better cognitive dysfunction, 1 week after cardiac surgery [12]. In contrast, another study which was performed in elderly patients after orthopedic surgeries, did not support the advantage of ketamine administration during anesthetic induction on POCD [13].

High level of extracellular concentration of glutamate is present in the rodent brain and spinal cord during ischemia or trauma [14, 15]. Previous research confirmed that high concentrations of glutamate, 100–500 mM, lead to cell death via activation of NMDA receptors [6]. In spite of potential toxic effect of high level of glutamate, its activity in a physiological concentration is absolutely required for normal brain function and long term improvement of learning and memory. Blockade of NMDA receptors leads to apoptosis in the developing brain [16]. Subsequently, complete blockade of NMDA receptors can cause serious complications such as coma, drowsiness, and hallucinations [17]. Based on the critical role of glutamate, its excitotoxicity effect should be blocked without interfering with its physiological action.

Although the concentration of glutamate increases to 10–100 fold of normal level after ischemia and brain injury, it remains high for 10–30 min and remains slightly high over days to weeks [18, 19]. Ikonomidou et al. suggested that such mild elevation of glutamate concentration may display a self-defense mechanism of the injured brain, which may improve survival of endangered neurons and facilitate tissue repair [20]. Subsequently, NMDA antagonist administration early after TBI (1–7 h after trauma) can harm neurons [21]. However, NMDA antagonist can play a protective role if it is administered prior to traumatic injury. Based on these findings, although glutamate kills neurons immediately after injury, it starts to assist brain repair shortly thereafter and preserves endangered neurons in long term. According to the research done by Ikonomidou et al., NMDA antagonists are not suitable neuroprotective drugs for use in human emergency medicine. The neuroprotective effect of NMDA antagonists is only in a situation that administered before injury and for a very short period (minutes) after that [20].

NMDA channels are open on average for only several milliseconds during normal synaptic activity and memantine cannot accumulate in the channels. Accordingly, synaptic activity continues unabated in the presence of memantine in physiologic condition. Fixed concentration of memantine blocked more NMDA receptors activity when the concentration of glutamate increased to pathologic levels. As a matter of fact, memantine cannot block NMDA receptor activity in normal neurological function but it is effective on blockade of receptor at higher concentrations. Subsequently, memantine becomes a very effective NMDA receptor blocker under excitotoxic conditions and prolonged activation of NMDA receptors [8].

Due to the critical effect of memantine on NMDA receptors in physiologic and pathologic conditions, it is reasonable to see the positive neuroprotection during cardiac surgeries. The pre-operative administration of memantine can protect neurons from excessive amount of glutamate released during cardiopulmonary bypass, whereas it does not interfere with normal level of glutamate function [22].

In addition, our study demonstrates strong positive effect on patient’s cognitive function in long term. Patients are in a high risk of vascular dementia after cardiac surgeries. In chronic disorders, the NMDA receptors become hyperactive for longer periods of time than occur during normal neurotransmission with a low level of glutamate. It is obvious that in neuronal damage in chronic disorders the elevation of extracellular glutamate is not necessary to induce an excitotoxic mechanism. In this situation NMDA receptors activity is increased because of relief from normal Mg2+ Blockade. These NMDA receptors over activity lead to neuronal injury or apoptotic-like cell death. Accordingly, memantine can affect NMDA receptors over activity in the presence of low glutamate concentration [23]. In parallel with the mentioned mechanism in this study, patients who received memantine for 3 months after surgery showed significant improvement in their cognitive function.

Moreover, previous studies showed that Memantine rescues transient cognitive impairment induced by High-Molecular-Weight Aβ Oligomers in mice [24]. Hence, effect of memantine on POCD is justifiable with the blockade of glutamate response on NMDA channel by blocking excessive calcium influx into the cell and reduction of Aβ formation in neurons [25].

Conclusion

Protective effect of memantine on POCD can be presented by its selective affinity to NMDA channel in different concentration of glutamate. Memantine blocks the NMDA channel during ischemia and early after that. Consequently, memantine protects brain from toxic effect of glutamate’s high concentration. Whereas, memantine maintains the normal action of glutamate in physiologic concentration and does not interrupt brain learning function.

It is hypothesized that pre-operative administration of memantine protects patients from early post-operative cognitive dysfunction in patients who undergo cardiac surgeries. Memantine does not have any drug interaction and patients did not contribute to any adverse effects when receive memantine. In conclusion, memantine is a safe neuroprotective agent against POCD after cardiac surgeries and it is tolerated well by patients pre- and post-operatively.

Study limitations

Due to the transient high concentration of glutamate after acute injury, it might be promising to design a study with pre-operative single high-dose of memantine. Because of financial limitations, paraclinic imaging has not been included in this study. For future studies paraclinic imaging, before and after surgery, is recommended in order to better provide brain changes comparison after cardiac surgeries. In this study, neither patients nor the personnel who performed tests were blind. It is worth mentioning that patients did not receive any placebo. Subsequently, double-blind, placebo-controlled studies are recommended.

Abbreviations

ANOVA: 

Applying repeated measures analysis of variance

Aβ: 

Amyloid beta

CABG: 

Coronary artery bypass graft

NMDA: 

N-methyl-D-aspartate

POCD: 

Post-operative cognition dysfunction

SD: 

Standard deviation

TBI: 

Traumatic brain injury

WMT: 

Wechsler memory test

Declarations

Acknowledgments

The authors would like to thank the medical team and staff at Tehran Heart Center for their assistance and dedication.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials

Not applicable.

Authors’ contributions

SG contributed in the conception and design of the study, data collation and manuscript preparation. PG contributed in the design of the study and gave revisions of the manuscript. AT contributed in the design of the study, gave revisions of the manuscript and supervised the study. AK performed cardiac surgeries. MN contributed in the design of the study. AS performed cardiac surgeries. AJ conducted the statistical analysis. All authors read and approved the final manuscript.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Hematology and Oncology Research Center, Tabriz University of Medical Sciences
(2)
Departments of Pharmacotherapy, Faculty of Pharmacy, Tehran University of Medical Sciences
(3)
Tehran Heart Center, Tehran University of Medical Sciences
(4)
Memory and Behavioral Neurology Department, Roozbeh Hospital, Tehran University of Medical Sciences

References

  1. Roach GW, Kanchuger M, Mangano CM, Newman M, Nussmeier N, Wolman R, Aggarwal A, Marschall K, Graham SH, Ley C. Adverse cerebral outcomes after coronary bypass surgery. Multicenter study of Perioperative ischemia research group and the Ischemia Research and Education Foundation investigators. N Engl J Med. 1996;335(25):1857–63.View ArticlePubMedGoogle Scholar
  2. Ghaffary S, Hajhossein Talasaz A, Ghaeli P, Karimi A, Salehiomran A, Hajighasemi A, Bina P, Darabi S, Jalali A, Dianatkhah M, Noroozian M, Shahmansouri N. Association between Perioperative parameters and cognitive impairment in post-cardiac surgery patients. J Teh Univ Heart Ctr. 2015;10(2):85–92.View ArticleGoogle Scholar
  3. Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H, Jones RH, Mark DB, Reves JG, Blumenthal JA. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med. 2001;344(6):395–402.View ArticlePubMedGoogle Scholar
  4. Selnes OA, Royall RM, Grega MA, Borowicz LM Jr, Quaskey S, McKhann GM. Cognitive changes 5 years after coronary artery bypass grafting: is there evidence of late decline. Arch Neurol. 2001;58(4):598–604.View ArticlePubMedGoogle Scholar
  5. Van Harten AE, Scheeren TW, Absalom AR. A review of postoperative cognitive dysfunction and neuroinflammation associated with cardiac surgery and anaesthesia. Anaesthesia. 2012;67(3):280–93.View ArticlePubMedGoogle Scholar
  6. Parfenova H, Basuroy S, Bhattacharya S, Tcheranova D, Qu Y, Regan RF, Leffler CW. Glutamate induces oxidative stress and apoptosis in cerebral vascular endothelial cells: contributions of HO-1 and HO-2 to cytoprotection. Am J Phys Cell Phys. 2006;290(5):C1399–410.View ArticleGoogle Scholar
  7. Albin R, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology. 1992;42(4):733–8.View ArticlePubMedGoogle Scholar
  8. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 2006;5(2):160–70.View ArticlePubMedGoogle Scholar
  9. Newman M, Grocott H, Mathew J, White WD, Landolfo K, Reves JG, Laskowitz DT, Mark DB, Blumenthal JA. Report of the substudy assessing the impact of neurocognitive function on quality of life 5 years after cardiac surgery. Stroke. 2001;32(12):2874–81.View ArticlePubMedGoogle Scholar
  10. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid. Brain Res. 2002;958(1):210–21.View ArticlePubMedGoogle Scholar
  11. Meythaler J, Brunner R, Johnson A, Novack T. Amantadine to improve Neurorecovery in traumatic brain injury–associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil. 2002;17(4):300–13.View ArticlePubMedGoogle Scholar
  12. Hudetz JA, Iqbal Z, Gandhi SD, Patterson KM, Byrne AJ, Hudetz AG, Pagel PS, Warltier DC. Ketamine attenuates post-operative cognitive dysfunction after cardiac surgery. Acta Anaesthesiol Scand. 2009;53(7):864–72.View ArticlePubMedGoogle Scholar
  13. Lee KH, Kim JY, Kim JW, Park JS, Lee KW, Jeon SY. Influence of Ketamine on early postoperative cognitive function after orthopedic surgery in elderly. Anesth Pain Med. 2015;5(5):e28844.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 1990;13:171–82.View ArticlePubMedGoogle Scholar
  15. Beal M. Mechanisms of excitotoxicity in neurologic diseases. FASEB. 1992;6(15):3338–44.Google Scholar
  16. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vöckler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999;283(5398):70–4.View ArticlePubMedGoogle Scholar
  17. Koroshetz WJ, Moskowitz MA. Emerging treatments for stroke in humans. Trends Pharmacol Sci. 1996;17(6):227–33.View ArticlePubMedGoogle Scholar
  18. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem. 1984;43(5):1369–74.View ArticlePubMedGoogle Scholar
  19. Baker AJ, Moulton RJ, MacMillan VH, Shedden PM. Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans. J Neurosurgery. 1993;79(3):369–72.View ArticleGoogle Scholar
  20. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury. Lancet Neurol. 2002;1(6):383–6.View ArticlePubMedGoogle Scholar
  21. Ikonomidou C, Stefovska V, Turski L. Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc Natl Acad Sci U S A. 2000;97(23):12885–90.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Shaaban Ali M, Harmer M, Kirkham F. Cardiopulmonary bypass temperature and brain function. Anaesthesia. 2005;60:365–72.View ArticlePubMedGoogle Scholar
  23. Globus MY, Busto R, Lin B, Schnippering H, Ginsberg MD. Detection of free radical activity during transient global ischemia and recirculation: effects of intra-ischemic brain temperature modulation. J Neurochem. 1995;65(3):1250–6.View ArticlePubMedGoogle Scholar
  24. Figueiredo CP, Clarke JR, Ledo JH, Ribeiro FC, Costa CV, Melo HM, Mota-Sales AP, Saraiva LM, Klein WL, Sebollela A, DeFelice FG, Ferreira ST. Memantine rescues transient cognitive impairment caused by high-molecular-weight a Oligomers but not the persistent impairment induced by low-molecular-weight Oligomers. J Neurosci. 2013;33(23):9626–34.View ArticlePubMedGoogle Scholar
  25. Li XM, Shao MT, Wang JJ, Wang YL. Relationship between post-operative cognitive dysfunction and regional cerebral oxygen saturation and beta-amyloid protein. J Zhejiang Univ Sci B. 2014;15(10):870–8.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement